Jagsonpal Pharmaceuticals Reports Q2FY27 Results with 29% Consolidated Revenue Growth
Jagsonpal Pharmaceuticals Ltd · Investor Presentation · 29 Oct 2026, 12:18 am
Jagsonpal Pharmaceuticals Reports Q2FY27 Results with 29% Consolidated Revenue Growth Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, driven by 9.3% standalone sales growth (₹814 Mn) and the consolidation of Aequitas Healthcare. Standalone EBITDA reached ₹185 Mn (22.7% margin) with PAT at ₹126 Mn. For H1FY27, standalone revenue rose 9.0% YoY to ₹1,636 Mn, while EBITDA and PAT grew 11.3% and 10.3% to ₹375 Mn and ₹258 Mn, respectively. Following an 85% stake buy in Aequitas and a 200% dividend payout, cash stood at ₹1,347 Mn as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Jagsonpal Pharmaceuticals Ltd
- Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M · 03 Nov 2026
- Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27 Earnings Conference call on October 29, 2026 at 02:00 P.M. · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter ended September 30, 2026. · 29 Oct 2026
- Unaudited Financial Results (Standalone & Consolidated for the quarter and half year ended September 30, 2026. · 28 Oct 2026
- Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
- Outcome of Board Meeting held on October 28, 2026 along with Unaudited Financial Results(Standalone & Consolidated) for the quarter and half year ended September 30, 2026 · 28 Oct 2026
- JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 28 Oct 2026
- Intimation of Analysts/Investors Conference Call · 29 Oct 2026
